Olumiant contains the active ingredient baricitinib, which is classified as an oral Janus kinase (JAK) inhibitor.
Understanding Baricitinib and its Function
- Baricitinib is the primary component of Olumiant.
- It works by inhibiting the activity of Janus kinase enzymes.
- These enzymes play a role in the inflammatory processes and immune responses in the body.
- By blocking JAK activity, baricitinib helps to reduce inflammation and other immune-related symptoms.
Olumiant's Specific Use
- Olumiant is approved by the FDA to treat adults with severe alopecia areata (AA). (1)
- Severe AA is defined as 50% or more scalp hair loss. (2)
- The FDA approval for AA occurred in June 2022. (1)
Olumiant: Key Component Summary
| Component | Description | Function |
|---|---|---|
| Baricitinib | Oral Janus kinase (JAK) inhibitor | Inhibits JAK enzymes, reducing inflammation and immune responses |
In summary, Olumiant's therapeutic effect is primarily due to its active ingredient, baricitinib, a JAK inhibitor designed to address inflammatory and immune-related conditions.
